Etanercept

INVENTION

Etanercept was developed by the company Immunex which was bought out by Amgen . The product is marketed jointly by Amgen and Wyeth .

MODE OF ACTION

Tumor necrosis factor-alpha (TNFα) is a Cytokine produced by Monocyte s and Macrophage s, two types of White Blood Cell s. It mediates the immune response by increasing the transport of white blood cells to sites of Inflammation . Inhibition of its action by etanercept reduces the inflammatory response which is especially useful for treating Autoimmune Disease s.

There are two types of TNF Receptor s: those found embedded in white blood cells that respond to TNF by releasing other cytokines, and ''soluble'' TNF receptors which are used to deactivate TNF and blunt the immune response. Etanercept mimics the inhibitory effects of naturally occurring soluble TNF receptors.

STRUCTURE

Etanercept is made from the combination of two naturally occurring soluble human 75-kilodalton TNF receptors linked to an Fc portion of an IgG1. The effect is an artificially engineered Antibody .

EXTERNAL LINKS

Official site

Information About ™

Etanercept

Information About ^{^™}